Glucocorticoid-resistant asthma: More than meets the eye

Journal of Asthma

Volumn 50, Issue 10, 2013, Pages 1036-1044

  Reddy, Divya ^a   Little, Frederic F ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Asthma; Glucocorticoids; Poorly controlled; Refractory; Severe

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; PREDNISONE; SALBUTAMOL;

ADULT; ARTICLE; ASTHMA; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; ECHOCARDIOGRAPHY; HUMAN; HUMAN TISSUE; LABORATORY TEST; MALE; OPEN LUNG BIOPSY; PRESCRIPTION; SMOKING;

ADULT; ASTHMA; DRUG RESISTANCE; GLUCOCORTICOIDS; HUMANS; LUNG; MALE;

EID: 84887785995     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.3109/02770903.2013.831870     Document Type: Article

References (67)

1. Bel EH, Sousa A, Fleming L, Bush A, Chung KF, Versnel J, Wagener AH, et al. Diagnosis and definition of severe refractory asthma: An international consensus statement from the Innovative Medicine Initiative (IMI). Thorax 2011;66:910-917.
2. Chanez P, Wenzel SE, Anderson GP, Anto JM, Bel EH, Boulet L-P, Brightling CE, et al. Severe asthma in adults: What are the important questions? J Allergy Clin Immunol 2007;119:1337-1348.
3. Chung KF, Godard P, Adelroth E, Ayres J, Barnes N, Barnes P, Bel E, et al. Difficult/therapy-resistant asthma: The need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. European Respiratory Society. Eur Respir J 1999;13:1198-1208.
4. Barnes PJ, Greening AP, Crompton GK. Glucocorticoid resistance in asthma. Am J Respir Crit Care Med 1995;152:S125-S140.
5. Akinbami LJ, Moorman JE, Bailey C, Zahran HS, King M, Johnson CA, et al. Trends in asthma prevalence, health care use, and mortality in the United States, 2001-2010. NCHS Data Brief 2012; 94:1-8.
6. Proceedings of the ATS workshop on refractory asthma: Current understanding, recommendations, and unanswered questions. American Thoracic Society. Am J Respir Crit Care Med 2000;162:2341-2351.
7. Barnett SBL, Nurmagambetov TA. Costs of asthma in the United States: 2002-2007. J Allergy Clin Immunol 2011;127:145-152.
8. Jang AS. Steroid response in refractory asthmatics. Korean J Intern Med 2012;27:143-148.
9. Chen Y, Dales R, Krewski D, Breithaupt K. Increased effects of smoking and obesity on asthma among female Canadians: The National Population Health Survey, 1994-1995. Am J Epidemiol 1999;150:255-262.
10. Akinbami OJ, Moorman JE, Liu X. Asthma prevalence, health care use, and mortality: United States, 2005-2009. 2011;32:1-16.
11. Bartolomei-Díaz JA, Amill-Rosario A, Claudio L, Hernández W. Asthma mortality in Puerto Rico: 1980-2007. J Asthma 2011;48: 202-209.
12. Wenzel S. Severe asthma in adults. Am J Respir Crit Care 2005; 172:149-160.
13. Jarjour NN, Erzurum SC, Bleecker ER, Calhoun WJ, Castro M, Comhair SAA, Chung KF, et al. Severe asthma: Lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. Am J Respir Crit Care Med 2012;185:356-362.
14. Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, Olin AC, et al. An official ATS clinical practice guideline: Interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011;184: 602-615.
15. Szefler SJ, Leung DY. Glucocorticoid-resistant asthma: Pathogenesis and clinical implications for management. Eur Respir J 1997; 10:1640-1647.
16. Demoly P, Jaffuel D, Mathieu M, Sahla H, Godard P, Michel FB, Bousquet J. Glucocorticoid insensitive asthma: A one year clinical follow up pilot study. Thorax 1998;53:1063-1065.
17. Barnes PJ, Adcock IM. Steroid resistance in asthma. Q J Med 1995; 88:455-468.
18. Chan MT, Leung DY, Szefler SJ, Spahn JD. Difficult-to-control asthma: Clinical characteristics of steroid-insensitive asthma J Allergy Clin Immunol 1998;101:594-601.
19. Barnes NC. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir Crit Care Med 2004;170:830-831.
20. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids - new mechanisms for old drugs. N Engl J Med 2005;353: 1711-1723.
21. Ito K, Chung KF, Adcock IM. Update on glucocorticoid action and resistance. J Allergy Clin Immunol 2006;117:522-543.
22. Urnov FD, Wolffe AP. Chromatin remodeling and transcriptional activation: The cast (in order of appearance). Oncogene 2001;20: 2991-3006.
23. Leung DY, Hamid Q, Vottero A, Szefler SJ, Surs W, Minshall E, Chrousos GP, et al. Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor beta. J Exp Med 1997;186:1567-1574.
24. Sher ER, Leung DY, SursW, Kam JC, Zieg G, Kamada AK, Szefler SJ. Steroid-resistant asthma. Cellular mechanisms contributing to inadequate response to glucocorticoid therapy. J Clin Invest 1994; 93:33-39.
25. Irusen E, Matthews JG, Takahashi A, Barnes PJ, Chung KF, Adcock IM. p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: Role in steroid-insensitive asthma. J Allergy Clin Immunol 2002;109: 649-657.
26. Adcock IM, Lane SJ. Corticosteroid-insensitive asthma: Molecular mechanisms. J Endocrinol 2003;178:347-355.
27. Savory JGA, Hsu B, Laquian IR, Giffin W, Reich T, Haché RJG, Lefebvre YA. Discrimination between NL1- and NL2-mediated nuclear localization of the glucocorticoid receptor. Mol Cell Biol 1999;19:1025-1037.
28. Szatmáry Z, Garabedian MJ, Vilcek J. Inhibition of glucocorticoid receptor-mediated transcriptional activation by p38 mitogenactivated protein (MAP) kinase. J Biol Chem 2004;279: 43708-43715.
29. Cosío BG, Mann B, Ito K, Jazrawi E, Barnes PJ, Chung KF, Adcock IM. Histone acetylase and deacetylase activity in alveolar macrophages and blood mononocytes in asthma. Am J Respir Crit Care Med 2004;170:141-147.
30. Wenzel SE, Szefler SJ, Leung DY, Sloan SI, Rex MD, Martin R.J. Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med 1997;156:737-743.
31. Wenzel SE, Balzar S, Cundall M, Chu HW. Subepithelial basement membrane immunoreactivity for matrix metalloproteinase 9: Association with asthma severity, neutrophilic inflammation, and wound repair. J Allergy Clin Immunol 2003;111:1345-1352.
32. Cundall M, Sun Y, Miranda C, Trudeau JB, Barnes S, Wenzel S.E. Neutrophil-derived matrix metalloproteinase-9 is increased in severe asthma and poorly inhibited by glucocorticoids. J Allergy Clin Immunol 2003;112:1064-1071.
33. Althuis MD, Sexton M, Prybylski D. Cigarette smoking and asthma symptom severity among adult asthmatics. J Asthma 1999;36: 257-264.
34. Silverman RA. Cigarette smoking among asthmatic adults presenting to 64 emergency departments. Chest American College of Chest Physicians 2003;123:1472-1479.
35. Thomson NC. Asthma and cigarette smoking. Eur Respir J 2004; 24:822-833.
36. Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002;57:226-230.
37. Pedersen B, Dahl R, Karlström R, Peterson CG, Venge P. Eosinophil and neutrophil activity in asthma in a one-year trial with inhaled budesonide. The impact of smoking. Am J Respir Crit Care Med 1996;153:1519-1529.
38. Ilowite JS, Bennett WD, Sheetz MS, Groth ML, Nierman D.M. Permeability of the bronchial mucosa to 99mTc-DTPA in asthma Am Rev Respir Dis 1989;139:1139-1143.
39. Chalmers GW, Macleod KJ, Thomson L, Little SA, McSharry C, Thomson NC. Smoking and airway inflammation in patients with mild asthma. Chest 2001;120:1917-1922.
40. Costabel U, Bross KJ, Reuter C, Rühle KH, Matthys H. Alterations in immunoregulatory T-cell subsets in cigarette smokers A phenotypic analysis of bronchoalveolar and blood lymphocytes Chest 1986;90:39-44.
41. Carroll N, Elliot J, Morton A, James A. The structure of large and small airways in nonfatal and fatal asthma. Am Rev Respir Dis 1993;147:405-410.
42. Hamid Q, Song Y, Kotsimbos TC, Minshall E, Bai TR, Hegele RG, Hogg JC. Inflammation of small airways in asthma. J Allergy Clin Immunol 1997;100:44-51.
43. Kraft M, Djukanovic R, Wilson S, Holgate ST, Martin RJ. Alveolar tissue inflammation in asthma. Am J Respir Crit Care Med 1996; 154:1505-1510.
44. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998;12: 1346-1353.
45. Goleva E, Hauk PJ, Boguniewicz J, Martin RJ, Leung DYM. Airway remodeling and lack of bronchodilator response in steroid-resistant asthma. J Allergy Clin Immunol 2007;120: 1065-1072.
46. Suissa S, Ernst P, Boivin JF, Horwitz RI, Habbick B, Cockroft D, Blais L, et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med 1994; 149(Pt 1):604-610.
47. Thomas M, Ziegenweidt von J, Lee AJ, Price D. High-dose inhaled corticosteroids versus add-on long-acting beta-agonists in asthma: An observational study. J Allergy Clin Immunol 2009;123: 116-121.e10.
48. Peters MJ, Adcock IM, Brown CR, Barnes PJ. Beta-adrenoceptor agonists interfere with glucocorticoid receptor DNA binding in rat lung. Eur J Pharmacol 1995;289:275-281.
49. Rider C, King EM, Holden NS, Giembycz MA, Newton R Inflammatory stimuli inhibit glucocorticoid-dependent transactivation in human pulmonary epithelial cells: Rescue by long-acting B2-adrenergic agonists. JPET 2011;338:860-869.
50. Martin RJ, Szefler SJ, Chinchilli VM, Kraft M, Dolovich M, Boushey HA, Cherniack RM, et al. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med 2002;165:1377-1383.
51. Sobande PO, Kercsmar CM. Inhaled corticosteroids in asthma management. Respir Care 2008;53:625-633-discussion, 633-634.
52. Hill JM, Tattersfield AE. Corticosteroid sparing agents in asthma Thorax 1995;50:577-582.
53. Shiner RJ, Nunn AJ, Chung KF, Geddes DM. Randomised, doubleblind, placebo-controlled trial of methotrexate in steroid-dependent asthma. Lancet 1990;336:137-140.
54. Stewart GE, Diaz JD, Lockey RF, Seleznick MJ, Trudeau WL, Ledford DK. Comparison of oral pulse methotrexate with placebo in the treatment of severe glucocorticosteroid-dependent asthma J Allergy Clin Immunol 1994;94(Pt 1):482-489.
55. Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, Fox H, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005;60:302-308.
56. Domingo C, Moreno A, José Amengual M, Montón C, Suárez D, Pomares X. Omalizumab in the management of oral corticosteroiddependent IGE-mediated asthma patients. Curr Med Res Opin 2011;27:45-53.
57. Polosa R, Casale T. Monoclonal antibodies for chronic refractory asthma and pipeline developments. Drug Discov Today 2012;17: 591-599.
58. Wenzel SE, Barnes PJ, Bleecker ER, Bousquet J, Busse W, Dahlen SE, Holgate ST, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009;179: 549-558.
59. Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, Buckley R, et al. Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006; 117:S525-S553.
60. Simon H-U, Seelbach H, Ehmann R, Schmitz M. Clinical and immunological effects of low-dose IFN-alpha treatment in patients with corticosteroid- resistant asthma. Allergy 2003;58:1250-1255.
61. Nair P, Pizzichini MMM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, Hargreave FE, et al. Mepolizumab for prednisonedependent asthma with sputum eosinophilia. N Engl J Med 2009; 360:985-993.
62. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973-984.
63. Antoniu SA. Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema. Curr Opin Investig Drugs 2010;11:1286-1294.
64. Takayama G, Arima K, Kanaji T, Toda S, Tanaka H, Shoji S, McKenzie AN, et al. Periostin: A novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals J Allergy Clin Immunol 2006;118:98-104.
65. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, Harris JM, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365:1088-1098.
66. Lukacs NW, Berlin AA, Franz-Bacon K, Sásik R, Sprague LJ, Ly TW, Hardiman G, et al. CRTH2 antagonism significantly ameliorates airway hyperreactivity and downregulates inflammation-induced genes in a mouse model of airway inflammation Am J Physiol Lung Cell Mol Physiol 2008;295: L767-L779.
67. Barnes PJ. New therapies for asthma: Is there any progress? Trends Pharmacol Sci 2010;31:335-343.